(Bold for FDA approved)
• Binds to benzodiazepine receptors at the GABA-A ligand-gated chloride channel complex</br>
• Enhances the inhibitory effects of GABA</br>
• Boosts chloride conductance through GABA-regulated channels</br>
• Inhibits neuronal activity presumably in amygdala-centered fear circuits to provide therapeutic benefits in anxiety disorders</br>
• Inhibiting actions in cerebral cortex may provide therapeutic benefits in seizure disorders</br>
• Inhibitory actions in spinal cord may provide therapeutic benefits for muscle spasms
• Some immediate relief with first dosing is common; can take several weeks with daily dosing for maximal therapeutic benefit
• Sedation
• Fatigue, depression
• Dizziness, ataxia, slurred speech, weakness
• Forgetfulness, confusion
• Hyperexcitability, nervousness
• Hypersalivation, dry mouth
• Pain at injection site
• Rare hallucinations, mania
• Rare hypotension
• Respiratory depression, especially when taken with CNS depressants in overdose
• Rare hepatic dysfunction, renal dysfunction, blood dyscrasias
unusual
common
• Wait
• Wait
• Wait
• Lower the dose
• Take largest dose at bedtime to avoid sedative effects during the day
• Switch to another agent
• Administer flumazenil if side effects are severe or life-threatening
• Oral: 4–40 mg/day in divided doses
• Intravenous (adults): 5 mg/minute
• Intravenous (children): 0.25 mg/kg every 3 minutes
• Tablet 2 mg, 5 mg, 10 mg
• Nasal 5 mg/spray, 7.5 mg/spray, 10 mg/ spray
• Concentrate 5 mg/mL
• Solution 5 mg/5 mL
• Injection 10 mg/2 mL, 50 mg/10 mL
• Rectal gel 2.5
• Evidence of efficacy up to 16 weeks
• Risk of dependence, particularly for treatment periods longer than 12 weeks and especially in patients with past or current polysubstance abuse
• Not recommended for long-term treatment of seizure disorders
• Diazepam is a Schedule IV drug
• Patients may develop dependence and/or tolerance with long-term use
• Initial 2–2.5 mg, 1–2 times/day; increase gradually as needed
• Initial 2–2.5 mg, 1–2 times/day; increase gradually as needed
• Benzodiazepines have been used to treat anxiety associated with acute myocardial infarction
• Diazepam may be used as an adjunct during cardiovascular emergencies
• Initial 2–2.5 mg, 1–2 times/day; increase gradually as needed
• 6 months and up: initial 1–2.5 mg, 3–4 times/day; increase gradually as needed
• Parenteral: 30 days or older
• Rectal: 2 years or older
• Long-term effects of diazepam in children/ adolescents are unknown
• Should generally receive lower doses and be more closely monitored
• Possible increased risk of birth defects when benzodiazepines taken during pregnancy
• Because of the potential risks, diazepam is not generally recommended as treatment for anxiety during pregnancy, especially during the first trimester
• Drug should be tapered if discontinued
• Infants whose mothers received a benzodiazepine late in pregnancy may experience withdrawal effects
• Neonatal flaccidity has been reported in infants whose mothers took a benzodiazepine during pregnancy
• Seizures, even mild seizures, may cause harm to the embryo/fetus
• Some drug is found in mother’s breast milk
• Recommended either to discontinue drug or formula feed
• Effects of benzodiazepines on nursing infants have been reported and include feeding difficulties, sedation, and weight loss
Based on data Published online by Cambridge University Press
Compiled by Dr. Jash Ajmera